A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)

Cette étude passe en revue les données évaluant l'intérêt des conjugués anticorps-médicaments dans le traitement du cancer du poumon non à petites cellules

Résumé en anglais

Even though both targeted and immunotherapy-based therapies have been establishedas frontline standard-of-care for patients with advanced lung cancer, adverse events,resistance, and disease progression remain unavoidable in most instances. In thisscenario, chemotherapy is a popular salvage option, but it has restricted therapeuticindex. Antibody-drug conjugates (ADCs) have emerged as a viable option. ADCs combinethe specificity of monoclonal antibodies with the cytotoxic effects of chemotherapyto deliver cytotoxic payloads to cancer cells in a direct fashion. Among the promisingADCs used in advanced solid tumors, HER2 targeted ADCs of trastuzumab ematansine andtrastuzumab deruxtecan are key drugs in this field.